Cytogam

Biological CSL Behring
Total Payments
$2.1M
Transactions
31
Doctors
11
Companies
3

Payment Trends by Year

Year Amount Transactions Doctors
2022 $4,800 1 1
2021 $907.00 2 2
2020 $35,270 13 10
2019 $1.7M 5 1
2018 $321,298 10 1

Payments by Nature

Nature of Payment Amount Transactions Share
Royalty or License $1.7M 2 82.5%
Unspecified $321,250 9 15.4%
Consulting Fee $40,507 13 1.9%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,070 4 0.1%
Travel and Lodging $673.55 1 0.0%
Education $47.52 1 0.0%
Food and Beverage $22.08 1 0.0%

Payments by Type

General
$1.8M
22 transactions
Research
$321,250
9 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
A Randomized Trial to Prevent Congenital Cytomegalovirus CMV CSL Behring $321,250 0

Top Doctors Receiving Payments for Cytogam

Doctor Specialty Location Total Records
Unknown Salt Lake City, UT $2.0M 11
, MD Pediatrics Richmond, VA $17,296 4
, MD Pediatrics Minneapolis, MN $6,000 2
, MD Infectious Disease Boston, MA $4,000 3
John Fung Transplant Surgery Chicago, IL $3,407 2
Vinay Sundaram Los Angeles, CA $3,305 2
Josh Levitsky Chicago, IL $3,000 1
, M.D Surgery Los Angeles, CA $3,000 1
, M.D Obstetrics & Gynecology Winston Salem, NC $1,500 1
, M.D., PHD Transplant Surgery Houston, TX $1,328 2
, M.D Internal Medicine Cincinnati, OH $437.00 1
, MD Internal Medicine Miami, FL $47.52 1

About Cytogam

Cytogam is a biological associated with $2.1M in payments to 11 healthcare providers, recorded across 31 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.

Payment data is available from 2018 to 2022. In 2022, $4,800 was paid across 1 transactions to 1 doctors.

The most common payment nature for Cytogam is "Royalty or License" ($1.7M, 82.5% of total).

Cytogam is associated with 1 research study, including "A Randomized Trial to Prevent Congenital Cytomegalovirus CMV" ($321,250).